INTELLIGENT BIO SOLUTIONS INC.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
| Common stock · Treasury stock · Additional paid-in · Accumulated · Accumulated other comprehensive · Non- controlling · Total shareholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | capital | deficit | income (loss) | interest | equity | |
| Balance, June 30, 2025* | 732,326 | $7,323 | (12) | $(1) | $65,849,823 | $(62,533,065) | $(327,944) | $(182,312) | $2,813,824 |
| Issuance of restricted stock to vendors | 816 | 8 | - | - | 11,992 | - | - | - | 12,000 |
| Issuance of common stock, net of issuance costs At-the-Market Offerings | 12,326 | 123 | - | - | 213,627 | - | - | - | 213,750 |
| Common stock issued for warrants exercised, net of issuance costs | 164,367 | 1,644 | - | - | 3,331,987 | - | - | - | 3,333,631 |
| Foreign currency translation adjustment | - | - | - | - | - | - | 48,716 | - | 48,716 |
| Net loss | - | - | - | - | - | (2,983,006) | - | (11,986) | (2,994,992) |
| Balance, September 30, 2025 | 909,835 | 9,098 | (12) | (1) | 69,407,429 | (65,516,071) | (279,228) | (194,298) | 3,426,929 |
| Issuance of restricted stock to vendors | 9,236 | 92 | - | - | 61,483 | - | - | - | 61,575 |
| Issuance of common stock, net of issuance costs At-the-Market Offerings | 192,072 | 1,921 | - | - | 1,157,562 | - | - | - | 1,159,483 |
| Common stock issued for warrants exercised, net of issuance costs | 22,291 | 223 | - | - | 2,006 | - | - | - | 2,229 |
| Issuance of common stock, net of issuance costs | 105,000 | 1,050 | - | - | 8,912,009 | - | - | - | 8,913,059 |
| Foreign currency translation adjustment | - | - | - | - | - | - | 13,149 | - | 13,149 |
| Net loss | - | - | - | - | - | (2,677,590) | - | (9,023) | (2,686,613) |
| Balance, December 31, 2025 | 1,238,434 | 12,384 | (12) | (1) | 79,540,489 | (68,193,661) | (266,079) | (203,321) | 10,889,811 |
| Issuance of restricted stock to vendors | 2,390 | 24 | - | - | 11,976 | - | - | - | 12,000 |
| Common stock issued for warrants exercised, net of issuance costs | 644,349 | 6,444 | - | - | 934,128 | - | - | - | 940,572 |
| Issuance of restricted shares to employees | 116,000 | 1,160 | - | - | (1,160) | - | - | - | - |
| Share based compensation expense | - | - | - | - | 12,204 | - | - | - | 12,204 |
| Foreign currency translation adjustment | - | - | - | - | - | - | (233,631) | - | (233,631) |
| Net loss | - | - | - | - | - | (2,862,712) | - | (6,928) | (2,869,640) |
| Balance, March 31, 2026 | 2,001,173 | $20,012 | (12) | $(1) | $80,497,637 | $(71,056,373) | $(499,710) | $(210,249) | $8,751,316 |
| Common stock · Treasury stock · Additional paid-in · Accumulated · Accumulated other comprehensive · Non- controlling · Total shareholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | capital | deficit | income (loss) | interest | equity | |
| Balance, June 30, 2024* | 345,600 | $3,456 | (12) | $(1) | $61,002,841 | $(51,964,332) | $(712,614) | $(146,159) | $8,183,191 |
| Issuance of common stock upon exercise of warrants | 79,393 | 794 | - | - | 7,145 | - | - | - | 7,939 |
| Stock awards issued to employees | 9,950 | 100 | - | - | 189,945 | - | - | - | 190,045 |
| Issuance of restricted stock to vendors | 1,116 | 11 | - | - | 11,989 | - | - | - | 12,000 |
| Issuance of common stock, net of issuance costs At-the-Market Offerings | 1,717 | 17 | - | - | 34,494 | - | - | - | 34,511 |
| Foreign currency translation adjustment | - | - | - | - | - | - | 216,355 | - | 216,355 |
| Net loss | - | - | - | - | - | (2,685,633) | - | (9,166) | (2,694,799) |
| Balance, September 30, 2024 | 437,776 | 4,378 | (12) | (1) | 61,246,414 | (54,649,965) | (496,259) | (155,325) | 5,949,242 |
| Issuance of restricted stock to vendors | 811 | 8 | - | - | 11,992 | - | - | - | 12,000 |
| Issuance of common stock, net of issuance costs At-the-Market Offerings | 42,120 | 421 | - | - | 641,687 | - | - | - | 642,108 |
| Foreign currency translation adjustment | - | - | - | - | - | - | (143,165) | - | (143,165) |
| Net loss | - | - | - | - | - | (2,249,470) | - | (7,327) | (2,256,797) |
| Balance, December 31, 2024 | 480,707 | 4,807 | (12) | (1) | 61,900,093 | (56,899,435) | (639,424) | (162,652) | 4,203,388 |
| Issuance of restricted stock to vendors | 471 | 5 | - | - | 11,995 | - | - | - | 12,000 |
| Common stock issued for warrants exercised, net of issuance costs | 63 | 1 | - | - | (1) | - | - | - | - |
| Issuance of common stock, net of issuance costs At-the-Market Offerings | 198,200 | 1,982 | - | - | 3,161,063 | - | - | - | 3,163,045 |
| Foreign currency translation adjustment | - | - | - | - | - | - | 116,007 | - | 116,007 |
| Net loss | - | - | - | - | - | (2,543,526) | - | (7,148) | (2,550,674) |
| Balance, March 31, 2025 | 679,441 | $6,795 | (12) | $(1) | $65,073,150 | $(59,442,961) | $(523,417) | $(169,800) | $4,943,766 |
| * | Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025, throughout the unaudited condensed consolidated financial statements unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.